bms ASE80ms Granted Regulatory Approval Granted Regulatory Approval

bms Ophthalmic Medical has secured multiple patents for its groundbreaking inventions.

Single-use Sterile Ophthalmic Drug Delivery Device ASE80ms Granted Regulatory Approval

On October 31, 2023, bms' single-use sterile ophthalmic drug delivery device, the ASE80ms, received approval for Class II medical device registration, Registration Certificate Number: Hubei Provincial Medical Device Registration Approval No. 20232164604

The ASE80ms embodies the pinnacle of bms' decade-long commitment to innovative research and development in blood medical technology. It heralds the introduction of the first domestic production line for the extraction and preparation of autologous serum ASE, transitioning from the conventional test tube method to a more advanced blood bag method. This milestone signifies the realization of a comprehensive solution for the preparation and administration of ASE biotherapy.

bms' pioneering ASE technology rejuvenates your eyes, restoring a more hydrated, youthful, and radiant appearance.